Skip to main content
. Author manuscript; available in PMC: 2020 Sep 29.
Published in final edited form as: Kidney Int. 2018 May 16;94(2):303–314. doi: 10.1016/j.kint.2018.02.024

Figure 4.

Figure 4.

Treatment of Alport mice with LOXL2i normalizes renal morphology and function, but does not improve lifespan. (Panel A) Plasma LOXL2 activity in mice orally dosed with PAT-1251 relative to vehicle control mice (Ave % ± SEM) (Panels B-E) Wild type and Alport mice were treated with LOXL2i from 2-7 weeks of age and scored for % fibrosis (panel B), % glomerulosclerosis (panel C), blood urea nitrogen levels (BUN) (panel D) and albuminuria normalized to urinary creatinine as measured by ELISA (panel E). Panel F shows that lifespan of LOXL2i treated Alport mice is shorter than vehicle-treated Alport mice. Panel G shows BUN levels at 10 weeks (PAT-1251 dosing from weeks 2-10) and Panel H shows a significant reduction in podocyte numbers in LOXL2i-treated mice (weeks 2-7) relative to vehicle-treated mice. Mean ± SEM *p<0.05